Telehealth company Hims & Hers Health , known for its weight-loss drug business, is promising it can diversify away from its reliance on compounded GLP-1 sales in the U.S., but that may not happen soon enough for investors who are growing impatient.
Sign up here.
The company also disclosed recently that it learned in February of a U.S. Securities and Exchange Commission investigation.
At the same time, the company is facing new costs from its U.S. business and expansion into eight countries, inc… [3622 chars]
Source: Reuters | Published: 2026-03-02T14:16:03Z
Credit: Reuters
